InterMed Discovery GmbH Company Profile

21:49 EDT 18th September 2014 | BioPortfolio

InterMed Discovery is a world class natural product lead-discovery company, driving innovation through the generation of novel product candidates for the life science, food and cosmetics industries. Using one of the most powerful validated natural product discovery engines, InterMed Discovery generates proprietary product pipelines of functional ingredients and also supports partners in research and lead generation. Biologically characterised product leads are identified using IMD BIOPROFILING® and NPSilico®, which together comprise a proprietary bioinformatics platform drawing on screening results compiled over many years, complemented by primary biological and chemical research on natural products. InterMed Discovery adds to this the industry’s largest collections of pure compounds, sample fractions and mixtures as its source for potential natural product leads. The Company is located in Dortmund, Germany and was founded in 2006 as a management buyout of the Natural Products Research Unit of Bayer Healthcare. IMD entered into strategic cooperations with companies such as Cognis GmbH (now BASF SE) and Biotropics Malaysia Berhad. Further information on InterMed Discovery can be found at

News Articles [356 Associated News Articles listed on BioPortfolio]

Discovery expert

Drug discovery provider Sygnature Discovery Ltd. has appointed Gerry Thomas as its new Director of Business Development.

Synthon and MAB Discovery sign discovery agreement

Synthon Biopharmaceuticals BV and MAB Discovery GmbH announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets s...

Medicus International rebrands as Discovery London

Publicis Healthcare-owned medical communications group Medicus International has rebranded to Discovery London, thereby officially joining the Discovery worldwide brand. Discovery London will assume t...

ADDF, Harrington Discovery Give Inaugural Awards

Researchers from The Ohio State (Columbus) and Emory (Atlanta) Universities will be the first recipients of drug discovery funding and innovation support from a new partnership between the Alzheimer's...

Radikal Therapeutics, Inc.

Radikal Therapeutics is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a par...

Targeting Protein-Protein Interactions For Drug Discovery

Cambridge Healthtech Institute (CHI) organizes the annual Drug Discovery Chemistry (DDC) conference that focuses on drug discovery of small molecule candidates and challenges involved in their optimiz...

MAB Discovery signs antibody development pact with Genmab

German firm MAB Discovery agreed to use its in vivo antibody discovery platform to generate antibodies for Genmab and its aff -More- 

Sygnature Discovery appoints Dr Gerry Thomas as Director of Business Development

Sygnature Discovery Limited, the UK’s largest independent integrated drug discovery provider, today announced the appointment of Dr Gerry Thomas to the pivotal role of Director of Business Devel...

PubMed Articles [524 Associated PubMed Articles listed on BioPortfolio]

Antimalarial Drug Discovery: From Quinine to the Dream of Eradication.

The search for antimalarial remedies predates modern medicine and the concept of small molecule chemotherapy, yet has played a central role in the development of both. This history is reviewed in the ...

Simulation of Swanson's Literature-Based Discovery: Anandamide Treatment Inhibits Growth of Gastric Cancer Cells In Vitro and In Silico.

Swanson's literature-based discovery focus on resurrecting previously published but neglected knowledge. In this study, we propose a two-step model of the discovery process and generate a hypothesis b...

Cancer epigenetics drug discovery and development: the challenge of hitting the mark.

Over the past several years, there has been rapidly expanding evidence of epigenetic dysregulation in cancer, in which histone and DNA modification play a critical role in tumor growth and survival. T...

ICR Expands CanSAR Drug Discovery Platform.

The UK's Institute of Cancer Research, London has broadened its CanSAR knowledgebase, a cancer drug-discovery platform that integrates genomic, chemical, and pharmacologic data. The newly released Can...

UK academic drug discovery.

Clinical Trials [38 Associated Clinical Trials listed on BioPortfolio]

Discovery Elbow Multi-Center Prospective Study

The purpose of this prospective clinical trial is to document the performance and clinical outcomes of Biomet Discovery Elbow.

Effects of a Multi-Faceted Psychiatric Intervention Targeted at the Complex Medically Ill: a Randomized Controlled Trial

Background: somatic patients with psychiatric co-morbidities are a major challenge for the health care system. This study evaluated a psychiatric intervention targeted at the complex medic...

A Clinical Investigation of the Discovery™ Elbow System

The purpose of this study is to perform a five-year, multi-center prospective evaluation of the Discovery™ Elbow System for outcome and durability. Relief of pain and restoration of fun...

Biomarker Discovery and Validation in Lung Cancer

Lung cancer is responsible for the most deaths due to cancer each year in both men and women worldwide and once diagnosed, the 10 year survival rate is poor (

DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.

To prospectively evaluate if the analysis of genetic polymorphisms can be used to identify patients at risk of ventricular tachycardia. To evaluate the influence of ICD-based diagnostic i...

Companies [993 Associated Companies listed on BioPortfolio]

InterMed Discovery GmbH

InterMed Discovery is a world class natural product lead-discovery company, driving innovation through the generation of novel product candidates for the life science, food and co...

Discovery Health

Discovery Health Media includes the Discovery Health and FitTV television networks and online assets, including, as well as its Continuing Medical Education (CME) business and ...

Argenta Discovery Ltd.

Argenta Discovery is a privately held drug discovery company, applying its integrated medicinal chemistry, biology, ADMET and CADD expertise to drive drug discovery programmes. Argenta has a successfu...

Pyxis Discovery B.V.

The ambition of Pyxis Discovery is to be the preferred chemistry service provider for companies that are active in small molecule drug discovery. Pyxis Discovery's Smart approach of designing and ...

Med Discovery SA

Med Discovery’s mission is the discovery and development of highly specific protein drugs to treat uro-genital cancers. By combining biological drug discovery expertise with a strong in-house knowle...

More Information about "InterMed Discovery GmbH" on BioPortfolio

We have published hundreds of InterMed Discovery GmbH news stories on BioPortfolio along with dozens of InterMed Discovery GmbH Clinical Trials and PubMed Articles about InterMed Discovery GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of InterMed Discovery GmbH Companies in our database. You can also find out about relevant InterMed Discovery GmbH Drugs and Medications on this site too.

Search BioPortfolio:

Corporate Database Quicklinks

Searches Linking to this Company Record